Press releases
- Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
- Azenta to Participate in the Jefferies Global Healthcare Conference
- Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
- Azenta Announces CEO Succession Plan
- Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024
- Azenta Announces Fiscal 2024 Second Quarter Earnings Conference Call and Webcast
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 100.00 |
---|---|
High | 101.00 |
Low | 97.00 |
Bid | 95.00 |
Offer | 99.00 |
Previous close | 97.00 |
Average volume | -- |
---|---|
Shares outstanding | 53.92m |
Free float | 52.86m |
P/E (TTM) | -- |
Market cap | 2.78bn USD |
EPS (TTM) | -2.74 USD |
Data delayed at least 15 minutes, as of Dec 02 2021.
More ▼